Interaction Checker

Interacciones de Temsirolimus

Temsirolimus (Torisel) tiene 215 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 2; moderadas: 212; leves: 1; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (2)

  • CarbamazepinaanticonvulsivoGrave

    Temsirolimus The use of concomitant strong CYP3A4 inducers such as carbamazepine should be avoided with temsirolimus. (etiqueta de Carbamazepina, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoGrave

    Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (etiqueta de Itraconazol, Interacciones medicamentosas)

Interacciones moderadas (212)

  • AbataceptinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Abrocitinibinhibidor de JAKModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • AcarbosaantidiabéticoModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • AdalimumabinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • AlemtuzumabinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Alogliptinainhibidor de la DPP-4Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Alogliptina y metforminainhibidor de la DPP-4Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • AmiodaronaantiarrítmicoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Amlodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Amlodipino y atorvastatinabloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Amlodipino y benazeprilbloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Amlodipino y olmesartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Amlodipino y valsartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Armodafiniloestimulante del SNCModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • AtazanavirantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • AzatioprinainmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • AzelastinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Azelastina y fluticasonaantihistamínicoModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Baricitinibinhibidor de JAKModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • BeclometasonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Benazeprilinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Benazepril e hidroclorotiazidainhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • BetametasonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Bexagliflozinainhibidor de SGLT2Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Bosentáninductor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Bromfeniramina, pseudoefedrina y dextrometorfanoantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • BudesonidacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Canagliflozinainhibidor de SGLT2Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Captoprilinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • CarbinoxaminaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • CenobamatoanticonvulsivoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • CetirizinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • CiclesonidacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • CiclofosfamidainmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • CiclosporinainmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Cimetidinaantagonista H2Moderada

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • CiproheptadinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • CladribinaantimetabolitoModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Claritromicinaantibiótico macrólidoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • ClemastinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • ClobazambenzodiazepinaModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • ClobetasolcorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • ClorfenaminaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Dapagliflozinainhibidor de SGLT2Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Dapagliflozina y metforminainhibidor de SGLT2Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DarunavirantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Darunavir y cobicistatantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Deferasiroxsuplemento de hierroModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DeflazacortcorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DesloratadinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DesonidacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DexametasonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DexclorfeniraminaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DifenhidraminaantihistamínicoModerada

    At the discretion of the physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting… (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Diltiazembloqueador de los canales de calcioModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DimenhidrinatoantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DimetilfumaratoinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DoxilaminaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Doxilamina y piridoxinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • DronedaronaantiarrítmicoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Dulaglutidaagonista del receptor de GLP-1Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • EfavirenzantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Efavirenz, lamivudina y tenofovirantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Empagliflozinainhibidor de SGLT2Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Empagliflozina y metforminainhibidor de SGLT2Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Enalaprilinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Enalapril e hidroclorotiazidainhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Enalaprilatoinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Eritromicinaantibiótico macrólidoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • EslicarbazepinaanticonvulsivoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • EtanerceptinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • EtravirinaantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • EverolimusinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Exenatidaagonista del receptor de GLP-1Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Famotidinaantagonista H2Moderada

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Felodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • FenobarbitalbarbitúricoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Fenobarbital, hiosciamina, atropina y escopolaminabarbitúricoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Fentermina y topiramatoestimulante del SNCModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • FexofenadinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • FingolimodinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Fluconazolantifúngico azólicoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • FludrocortisonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • FlunisolidacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • FluocinonidacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • FluticasonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • FosamprenavirantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Fosaprepitantinhibidor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • FosfenitoínaanticonvulsivoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Fosinoprilinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Fosinopril e hidroclorotiazidainhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • GlibenclamidasulfonilureaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Glibenclamida y metforminasulfonilureaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • GlimepiridasulfonilureaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • GlipizidasulfonilureaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Glipizida y metforminasulfonilureaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • GriseofulvinaantifúngicoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • GuselkumabinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • HalobetasolcorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Hidrocodona y clorfenaminaopioideModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • HidrocortisonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • HidroxizinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Ibuprofeno y famotidinaAINEModerada

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Imatinibinhibidor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • InfliximabinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Insulina aspartainsulinaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Insulina degludecinsulinaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Insulina detemirinsulinaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Insulina glarginainsulinaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Insulina lisproinsulinaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Insulina regular (humana)insulinaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • IsoniazidaantibióticoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Isradipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Ketoconazolantifúngico azólicoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • LeflunomidainmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • LenacapavirantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • LevocetirizinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Linagliptinainhibidor de la DPP-4Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Linagliptina y metforminainhibidor de la DPP-4Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Liraglutidaagonista del receptor de GLP-1Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Lisinoprilinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • LoratadinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Lorlatinibinductor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • MeclozinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • MercaptopurinaantimetabolitoModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • MetforminabiguanidaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • MetilprednisolonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • MetotrexatoinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • MicofenolatoinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Mifepristonainhibidor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • MiglitolantidiabéticoModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Mirabegrónagonista beta-adrenérgicoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Mitapivatinductor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Mitotanoinductor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Modafiniloestimulante del SNCModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Moexiprilinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • MometasonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Nafcilinaantibiótico del grupo de las penicilinasModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • NatalizumabinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • NateglinidameglitinidaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • NefazodonaantidepresivoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • NevirapinaantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Nicardipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Nifedipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Nimodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Nisoldipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Nizatidinaantagonista H2Moderada

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • OcrelizumabinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • OlopatadinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • OxcarbazepinaanticonvulsivoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Palbociclibinhibidor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • PerampanelanticonvulsivoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Perindoprilinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Pimecrolimusinhibidor de la calcineurinaModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • PioglitazonatiazolidinedionaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Pioglitazona y glimepiridatiazolidinedionaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Pioglitazona y metforminatiazolidinedionaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • PonesimodinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Posaconazolantifúngico azólicoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • PrednisolonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • PrednisonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • PrimidonaanticonvulsivoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • PrometazinaantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Prometazina y codeínaopioideModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Prometazina y dextrometorfanoantihistamínicoModerada

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Quinaprilinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Quinapril e hidroclorotiazidainhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Ramiprilinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • Ranitidinaantagonista H2Moderada

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • RepaglinidameglitinidaModerada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • RifabutinaantibióticoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • RifampicinaantibióticoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • RifapentinaantibióticoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Ritlecitinibinhibidor de JAKModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • RitonavirantirretroviralModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • RituximabinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Saxagliptinainhibidor de la DPP-4Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Saxagliptina y metforminainhibidor de la DPP-4Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • SecukinumabinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Semaglutidaagonista del receptor de GLP-1Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • SirolimusinmunosupresorModerada

    TORISEL should be used with caution in persons with known hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any other component (including the excipients) of TORISEL. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Sitagliptinainhibidor de la DPP-4Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Sitagliptina y metforminainhibidor de la DPP-4Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • SunitinibModerada

    Concomitant use of TORISEL with sunitinib The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Suvorexantsedante-hipnóticoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Suzetriginainductor de CYP3A4Moderada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • TacrolimusinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Telmisartán y amlodipinoantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • TeriflunomidainmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Ticagrelorantiagregante plaquetarioModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Tirzepatidaagonista del receptor de GLP-1Moderada

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • TocilizumabinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • TofacitinibinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • TopiramatoanticonvulsivoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Trandolaprilinhibidor de la ECAModerada

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (etiqueta de Temsirolimus, Interacciones medicamentosas)

  • TriamcinolonacorticosteroideModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • UpadacitinibinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • UstekinumabinmunosupresorModerada

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Verapamilobloqueador de los canales de calcioModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • Voriconazolantifúngico azólicoModerada

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etiqueta de Temsirolimus, Advertencias y precauciones)

Menciones leves (1)

  • Desipraminaantidepresivo tricíclicoLeve

    Drug Interactions Effect of Temsirolimus on CYP2D6 or CYP3A The concentration of desipramine, a CYP2D6 substrate, was unaffected when 25 mg of temsirolimus was co-administered. (etiqueta de Temsirolimus, Interacciones medicamentosas)

Compruebe Temsirolimus frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.